Hanno Roder
Mayo Clinic
12 Papers
44 Citations
Hanno Roder is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Tauopathy & Tau protein. The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy
Zdenek Berger,Hanno Roder,Amanda Hanna,Aaron Carlson,Vijayaraghavan Rangachari,Mei Yue,Zbigniew K. Wszolek,Karen H. Ashe,Joshua Knight,Dennis W. Dickson,Cathy A. Andorfer,Terrone L. Rosenberry,Jada Lewis,Mike Hutton,Christopher Janus +14 more
TL;DR: Accumulation of early-stage aggregated tau species, before the formation of NFT, is associated with the development of functional deficits during the pathogenic progression of tauopathy, suggesting that NFTs are not the major neurotoxic tau protein species, at least during the early stages of pathogenesis.
509
Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy
TL;DR: The findings suggest that the onset of abnormal tau biochemistry and coincident cognitive deficits in the rTg4510 mouse model is sex-dependent with females being affected earlier and more aggressively than males.
131
Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease.
Hanno Roder,Mike Hutton +1 more
TL;DR: Some of the main therapeutic ideas presently advanced in the field of tau, not only as a pathologic marker, but as a therapeutic target, and their molecular rationales are discussed.
22
Inhibition of PHF-like tau hyperphosphorylation in SH-SY5Y cells and rat brain slices by K252a.
Gabriele Hübinger,Silvia Geis,Sylvie LeCorre,Susanne Mühlbacher,Sandra Gordon,R. Paul Fracasso,Fred Hoffman,Sandrine Ferrand,Hans Klafki,Hanno Roder +9 more
TL;DR: K252a was uniquely able to completely suppress the okadaic acid-induced tau hyperphosphorylation in SH-SY5Y cells and rat brain slices by way of including ERK2 in its inhibitory spectrum, and to conserve the normal binding of tau to tubulin.
17
Patent
N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
Heidi Sahagun-Krause,Olivier Thillaye Du Boullay,Thillaye Du Boullay Valerie,Casiraghi Laura,Hans-Wolfgang Klafki,Pierfausto Seneci,Braxmeier Tobias,Silvia Müller,Wolfgang Fröhner,Barbara Monse,Sandra Gordon,Hanno Roder +11 more
- 04 Dec 2002
TL;DR: In this paper, the use of N-carbacycle monosubstituted indolocarbazole compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes, as a chemotherapeutic for the treatment of various malignant diseases, and for treating diseases caused by malfunctioning of specific signaling pathways, such as Alzheimer's disease.
5